GARDP Receives Funding From the Government of Japan as Part of Its Ongoing Contribution To Fight Against Drug-Resistant Infections

The Global Antibiotic Research and Development Partnership (GARDP) has been granted additional funding by the Government of Japan to support the fight against drug-resistant infections, with the funding contributing to the research and development of new treatments for bacterial infections posing the greatest threat to global health.

Japan announced funding of approximately 200 million yen (US $1.8 million) which covers the period April 2021 to March 2022. The funding is part of a 1 billion yen (US $9 million) pledge to GARDP for the period 2020 to 2025. Japan has previously contributed approximately 200 million yen as part of this pledge.

The investment by Japan will be used to accelerate research and development into treatments for infections caused by the drug-resistant ‘priority pathogens’ identified by the World Health Organization (WHO) as critically in need of new antibiotic development. This includes funding for GARDP efforts to develop treatments for hospital acquired infections, sexually transmitted infections and infections in newborns. The funding will also support work to ensure these treatments are used responsibly and made accessible to every person who needs them.